Drug Repurposing of Octreotide as a Selective Apelin Receptor Antagonist Against Pathological Angiogenesis: Integrated Virtual Screening and Zebrafish Validation
Our findings identified octreotide as a novel APJ antagonism with high translational potential, offering a dual advantage-targeting pathological neovascularization while preserving physiological VEGF signaling. These findings support its repurposing as a precision therapy for ROP and other ocular neovascular disorders.
Authors
- Yongfang Yao (ORCID: https://orcid.org/0000-0001-6455-1213)
- Chuanjun Song (ORCID: https://orcid.org/0000-0001-7733-578X)
- Mingmei Guo
- Moran Sun (ORCID: https://orcid.org/0000-0001-6577-0733)
- Hua Yang (ORCID: https://orcid.org/0000-0002-5518-5255)
- Liping Chen (ORCID: https://orcid.org/0009-0009-0018-9564)
- Yinuo Wang (ORCID: https://orcid.org/0009-0002-5952-1831)
Institutions
- Zhengzhou University (CN)
- Zhengzhou Business University (CN)
Publication Details
- Journal
- Journal of Ocular Pharmacology and Therapeutics
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1177/10807683251389401
- Primary Topic
- Apelin-related biomedical research
- Type
- article
- Field-Weighted Citation Impact
- 0.00